Dengue Testing Market Segmentation:
Test Type Segment Analysis
The NS1 antigen test segment is expected to hold the largest share of 38.4% in the dengue testing market over the assessed timeline. The critical role of this subtype in early detection is a major propeller behind this leadership. As evidence, the AHRQ study demonstrated the efficacy of these tests in identifying the cause of infection within 1–5 days of affliction, which ultimately reduces hospitalization costs by 30.4%. Adoption in this segment is further widening due to tightening government mandates. For instance, the National Vector Borne Disease Control Programme (NVBDCP) in India suggested accommodation of NS1 testing in outbreak zones, ensuring widespread use in high-risk areas.
End user Segment Analysis
The diagnostic laboratories segment is poised to dominate the dengue testing market with a 42.5% share by the end of 2034. This proprietorship is empowered by its pivotal significance as centralized testing hubs handling 70.2% of dengue cases in endemic regions, according to a report from the WHO. Furthermore, efforts from both government and private organizations to provide maximum financial and access support are attracting more consumers to enroll for these diagnoses. For instance, in 2023, the network of public and private laboratories in Brazil boosted testing capacity by 25.4%, enhancing efficiency and accessibility in high-burden areas.
Our in-depth analysis of the dengue testing market includes the following segments:
|
Segment |
Subsegments |
|
Test Type |
|
|
End user |
|
